ArticleCancer immunology, immunotherapy : CII2024

Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy.

Daiki Murata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.